HCPCS Level II code J2781 denotes an intravitreal injection of pegcetacoplan, 1 mg. As a drug-specific HCPCS Level II code for ophthalmic intravitreal therapy, J2781 matters nationally for billing, coverage determination, and specialty pharmacy distribution tied to retinal disease management. Its use captures drug acquisition and utilization for intravitreal pegcetacoplan therapy and supports claims processing and reimbursement for clinicians and facilities providing the injection.

Key payers included in the coverage landscape are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for intravitreal pegcetacoplan, common sites of service, and the payer mix relevant to national billing considerations. The publication outlines benchmark topics including standard billing practice for HCPCS Level II drug codes, common modifier usage patterns, and how payers typically approach coverage and prior authorization for intravitreal pharmacotherapies.

The report also summarizes policy and coding updates that affect HCPCS drug reporting, describes service line implications for ophthalmology clinics and outpatient surgical centers, and highlights data points readers can use for operational planning. Data not available in the input will be identified explicitly in the detailed sections.